… over-year increase for the first half of 2025. When diving … antibody-drug conjugate biotech Vincerx Pharma, oral KIT inhibitor developer … least 863 roles for the first half of 2025.  Several biopharmas have … the company's revenue normally supported by U.S …

Revenue for the six months ended 30 June rose 20% year-on-year to about £25.2m, or 21% on a constant currency basis. Adjusted EBITDA increased 30% to around £9.2m, while the company maintained a strong cash position of £11.8m despite paying a £5m dividend …

… pharmaceutical industry. Medicaid only accounts for a portion of many drugmakers' revenue … venture funding during the first half of the year, the first … 245 deals in the first half of the year, while … A agreements in the first half of 2025, which could …

… while state budget revenues and expenditures increased by … Export performance In the first half of 2025, total … cable equipment: +108% (+$44M) Pharmaceuticals: +120% (+$18M) Tourism services … foreign investment during the first half of the year, including …

… ? A) In the first half of 2025, we focused … India’s electronics manufacturing, pharmaceuticals, automobiles (especially EVs), textiles … , renewable energy, and pharmaceuticals driven by rate cuts, … While many have improved profitability post-pandemic, margins …

… put patients’ wellbeing ahead of profits. Among its concerns were aggressive … reminds doctors, nurse practitioners and pharmacists what the rules are. What … medicinal cannabis products in the first half of 2024 alone. But Ahpra …

… the biggest UK-listed company, pharma giant Astrazeneca, was itself considering … of the year, the lowest-first half since 1995. Indeed, virtually every … Mark Williams, Datasite Global Chief Revenue Officer. “Once regulatory clarity is …

… . After falling sharply in the first half, the Nifty Midcap and Smallcap … Durables, Pharma, and Healthcare were the major losers, seeing some profit booking …

… complex specialised fermentation-based active pharmaceutical ingredients (APIs), including probiotics, enzymes … be fully operational by the first half of F26. The third manufacturing … first half of 2025. On the financial front, the company's revenue …

… . After falling sharply in the first half, the Nifty Midcap and Smallcap … Durables, Pharma, and Healthcare were the major losers, seeing some profit booking …